[go: up one dir, main page]

PE20201345A1 - Receptores de celulas t, y celulas disenadas que expresan los mismos - Google Patents

Receptores de celulas t, y celulas disenadas que expresan los mismos

Info

Publication number
PE20201345A1
PE20201345A1 PE2020001533A PE2020001533A PE20201345A1 PE 20201345 A1 PE20201345 A1 PE 20201345A1 PE 2020001533 A PE2020001533 A PE 2020001533A PE 2020001533 A PE2020001533 A PE 2020001533A PE 20201345 A1 PE20201345 A1 PE 20201345A1
Authority
PE
Peru
Prior art keywords
cells
antibodies
bind
recognize
binding molecules
Prior art date
Application number
PE2020001533A
Other languages
English (en)
Inventor
Stephen Jacob Goldfless
Brian Belmont
Cameron Brandt
Alexandra Croft
David Jeffrey Huss
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of PE20201345A1 publication Critical patent/PE20201345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En la presente se proveen moleculas de union, como las que reconocen o se unen a un epitopo peptidico de un antigeno del cancer, como las expresadas en una celula cancerosa, incluidas las celulas infectadas con el virus del papiloma humano (VPH) o que contienen secuencias de ADN del VPH y/o aquellas que reconocen o unen un epitopo peptidico de VPH 16 E6 o E7, en el contexto de una molecula del complejo mayor de histocompatibilidad (MHC). Entre las moleculas de union provistas se encuentran los receptores de celulas T (TCR) o anticuerpos, incluyendo fragmentos de union al antigeno de los mismos, que se unen o reconocen dichos epitopos peptidicos. La presente invencion se refiere, ademas, a celulas disenadas por ingenieria genetica que comprenden dichas moleculas de union, por ejemplo, TCR o anticuerpos (y receptores de antigenos quimericos que contienen los anticuerpos), y usos de los mismos en la terapia celular adoptiva
PE2020001533A 2018-04-05 2019-04-03 Receptores de celulas t, y celulas disenadas que expresan los mismos PE20201345A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862653516P 2018-04-05 2018-04-05
US201862739145P 2018-09-28 2018-09-28
PCT/US2019/025676 WO2019195486A1 (en) 2018-04-05 2019-04-03 T cell receptors and engineered cells expressing same

Publications (1)

Publication Number Publication Date
PE20201345A1 true PE20201345A1 (es) 2020-11-25

Family

ID=66182684

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001533A PE20201345A1 (es) 2018-04-05 2019-04-03 Receptores de celulas t, y celulas disenadas que expresan los mismos

Country Status (18)

Country Link
US (2) US11471489B2 (es)
EP (1) EP3773908A1 (es)
JP (1) JP7410868B2 (es)
KR (1) KR102764123B1 (es)
CN (1) CN112566698A (es)
AU (1) AU2019249209A1 (es)
BR (1) BR112020019313A2 (es)
CA (1) CA3095027A1 (es)
CL (1) CL2020002545A1 (es)
CO (1) CO2020013499A2 (es)
IL (1) IL277703A (es)
MA (1) MA52193A (es)
MX (1) MX2020010460A (es)
PE (1) PE20201345A1 (es)
RU (1) RU2020135968A (es)
SG (1) SG11202009284TA (es)
TW (1) TWI840351B (es)
WO (1) WO2019195486A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072660B2 (en) 2016-10-03 2021-07-27 Juno Therapeutics, Inc. HPV-specific binding molecules
KR20200104284A (ko) 2017-10-03 2020-09-03 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
EP3810780A1 (en) * 2018-06-22 2021-04-28 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
WO2020010565A1 (zh) * 2018-07-12 2020-01-16 深圳华大生命科学研究院 Mart-1(27-35)表位特异性t细胞受体
WO2020214957A1 (en) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
CN113321726B (zh) * 2020-02-28 2024-05-28 香雪生命科学技术（广东）有限公司 一种识别hpv的t细胞受体
JP2023518578A (ja) * 2020-03-23 2023-05-02 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ Ｈｐｖ感染細胞を標的とするための組成物及び方法
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
WO2021243695A1 (en) * 2020-06-05 2021-12-09 Guangdong Tcrcure Biopharma Technology Co., Ltd. Tcr-t cell therapy targeting epstein-barr virus
US20230227526A1 (en) * 2020-06-09 2023-07-20 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
CA3167637A1 (en) * 2020-12-21 2022-06-30 Eric Escobar-Cabrera Stabilized tcr constructs and methods of use
WO2022155375A2 (en) * 2021-01-13 2022-07-21 Washington University MHC-INDEPENDENT TCRs AND METHODS OF MAKING AND USING SAME
CN114853878A (zh) * 2021-02-03 2022-08-05 香雪生命科学技术（广东）有限公司 一种针对hpv的高亲和力tcr
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
EP4322971A4 (en) * 2021-04-14 2025-05-28 Tscan Therapeutics, Inc. Binding proteins recognizing ha-2 antigen and uses thereof
US20240352087A1 (en) * 2021-07-14 2024-10-24 Emory University T Cell Receptors (TCR) to Human Papillomavirus Proteins, Compositions, and Uses Thereof
WO2023036169A1 (en) * 2021-09-07 2023-03-16 Corregene Biotechnology Co., Ltd. Antigen binding proteins and uses thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023086477A2 (en) * 2021-11-10 2023-05-19 Tscan Therapeutics, Inc. Binding proteins recognizing hpv16 e7 antigen and uses thereof
WO2023133296A2 (en) * 2022-01-07 2023-07-13 Sorrento Therapeutics, Inc. Engineered pd-l1-targeting gamma delta t cell receptors
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
CN115286690B (zh) * 2022-05-10 2023-06-20 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
CN117402232A (zh) * 2022-05-10 2024-01-16 广州医科大学 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
AU2024276276A1 (en) * 2023-05-22 2025-12-04 Precigen, Inc. T cell receptors generated as a result of hpv vaccine therapy and methods of treating patients with same
CN119569851A (zh) * 2023-09-05 2025-03-07 香雪生命科学技术（广东）有限公司 针对magea4的高亲和力tcr

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4777239A (en) 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1990007380A2 (en) 1988-12-28 1990-07-12 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
EP0557459B1 (en) 1990-11-13 1997-10-22 Immunex Corporation Bifunctional selectable fusion genes
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
CA2163427A1 (en) 1993-05-21 1994-12-08 Stephen D. Lupton Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
AU704601B2 (en) 1994-01-18 1999-04-29 Scripps Research Institute, The Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
EP2022856B1 (en) 1994-08-20 2011-09-14 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
JP2001521909A (ja) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド 糖タンパク質グリコフォームを含む方法及び組成物
US6355424B1 (en) 1997-12-12 2002-03-12 Digene Corporation Assessment of human papillomavirus-related disease
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
ID28040A (id) 1998-05-19 2001-05-03 Avidex Ltd Reseptor sel t yang dapat larut
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6500641B1 (en) 1999-05-06 2002-12-31 Wake Forest University School Of Medicine Compositions and methods for identifying antigens which elicit an immune response
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
PL218428B1 (pl) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
CA2425862C (en) 2000-11-07 2013-01-22 City Of Hope Cd19-specific redirected immune cells
WO2002077012A2 (en) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
ES2239246T3 (es) 2001-08-31 2005-09-16 Avidex Limited Receptor soluble de celulas t.
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1549748B1 (en) 2002-10-09 2014-10-01 Immunocore Ltd. Single chain recombinant t cell receptors
UA89350C2 (uk) 2002-12-16 2010-01-25 Дженентек, Інк. Гуманізоване антитіло, що зв'язує людський cd20
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
ES2708095T3 (es) 2003-11-05 2019-04-08 Roche Glycart Ag Anticuerpos de CD20 con afinidad de unión a receptor de Fc y función efectora incrementadas
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US7399467B2 (en) 2003-12-23 2008-07-15 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
DE602005022595D1 (de) 2004-06-29 2010-09-09 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
MX2007003910A (es) 2004-10-01 2007-06-07 Avidex Ltd Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
JP2008044848A (ja) 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
US20100003704A1 (en) 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP3584251A3 (en) 2007-05-31 2020-01-29 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
US20090117140A1 (en) 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
ATE528077T1 (de) 2007-12-07 2011-10-15 Miltenyi Biotec Gmbh Zentrifuge zur trennung einer probe in mindestens zwei komponenten
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
KR20090103571A (ko) 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
KR20090125629A (ko) 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
KR20090125628A (ko) 2008-06-02 2009-12-07 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
AU2009283194B2 (en) 2008-08-22 2014-10-16 Sangamo Therapeutics, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration
US20120141502A1 (en) 2009-04-20 2012-06-07 Eric Dixon Antibodies specific to e6 proteins of hpv and use thereof
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
EP3527585B1 (en) 2009-11-03 2022-02-16 City of Hope Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
AU2011215557B2 (en) 2010-02-09 2016-03-10 Sangamo Therapeutics, Inc. Targeted genomic modification with partially single-stranded donor molecules
EP2536758B1 (en) 2010-02-16 2019-01-02 Österreichische Akademie der Wissenschaften Anti-hpv e7 antibodies
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
KR101415554B1 (ko) 2010-09-13 2014-07-04 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련 질환 예방 또는 치료용 조성물
EP2625320B1 (en) 2010-10-08 2019-03-27 President and Fellows of Harvard College High-throughput single cell barcoding
WO2012048340A2 (en) 2010-10-08 2012-04-12 President And Fellows Of Harvard College High-throughput immune sequencing
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG193591A1 (en) 2011-03-23 2013-10-30 Hutchinson Fred Cancer Res Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN114835823A (zh) 2011-07-29 2022-08-02 宾夕法尼亚大学董事会 转换共刺激受体
EP2567972A1 (en) 2011-09-12 2013-03-13 Adriacell S.p.A. Antibodies against E7 protein of Human Papilloma Virus (HPV)
EP2776451B1 (en) 2011-11-11 2018-07-18 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
SG11201407175RA (en) 2012-05-03 2014-12-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
US9931359B2 (en) 2012-05-08 2018-04-03 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
MA37681B2 (fr) 2012-05-25 2020-07-29 Cellectis Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie
KR102264290B1 (ko) 2012-08-20 2021-06-10 프레드 헛친슨 켄서 리서치 센터 세포 면역요법을 위한 방법 및 조성물
ES2743738T3 (es) 2012-10-02 2020-02-20 Memorial Sloan Kettering Cancer Center Composiciones y métodos para inmunoterapia
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
KR20210108497A (ko) 2013-02-26 2021-09-02 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
JP2016521975A (ja) 2013-05-15 2016-07-28 サンガモ バイオサイエンシーズ， インコーポレイテッド 遺伝的状態の処置のための方法および組成物
EP3004337B1 (en) 2013-05-29 2017-08-02 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
MX375056B (es) * 2013-06-26 2025-03-06 Xlifesc Ltd Receptor de celulas t de alta estabilidad y metodo de preparacion y aplicacion del mismo.
RU2713333C2 (ru) 2013-07-15 2020-02-04 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Способы получения т-клеток против антигена папилломавируса человека
CA2918216C (en) 2013-07-15 2023-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 e6 t cell receptors
CN103342738B (zh) 2013-07-24 2015-02-18 广州恒上医药技术有限公司 人乳头瘤病毒e6蛋白可诱发同源蛋白间交叉反应性抗体的精细表位肽
US9547006B2 (en) 2013-08-08 2017-01-17 Institut Pasteur Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
NZ758715A (en) 2013-10-31 2023-01-27 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
HUE066758T2 (hu) 2014-03-11 2024-09-28 Cellectis Eljárás allogén transplantációval kompatibilis T-sejtek elõállítására
US10627411B2 (en) 2014-03-27 2020-04-21 British Columbia Cancer Agency Branch T-cell epitope identification
CN108138183A (zh) 2014-04-18 2018-06-08 爱迪塔斯医药公司 用于癌症免疫疗法的crispr-cas相关方法、组合物和组分
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
BR112015015380A2 (pt) * 2014-07-11 2017-07-11 Intel Corp dispositivos eletrônicos inclináveis e estiráveis e métodos
WO2016016341A1 (en) 2014-07-29 2016-02-04 Cellectis EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
CN107074970B (zh) * 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
SG11201702060VA (en) 2014-09-15 2017-04-27 Abvitro Inc High-throughput nucleotide library sequencing
KR102781429B1 (ko) * 2014-10-31 2025-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
EP3271382B1 (en) 2015-03-16 2020-02-12 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
AU2016261356A1 (en) * 2015-05-08 2018-01-04 Eureka Therapeutics, Inc. Constructs targeting HPV16-E7 peptide/MHC complexes and uses thereof
CA2991301A1 (en) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
UA126373C2 (uk) 2015-12-04 2022-09-28 Новартіс Аг Композиція і спосіб для імуноонкології
AU2016369490C1 (en) 2015-12-18 2021-12-23 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
KR20230038299A (ko) 2016-05-06 2023-03-17 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 및 그의 제조 방법
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
US11072660B2 (en) 2016-10-03 2021-07-27 Juno Therapeutics, Inc. HPV-specific binding molecules
KR102877389B1 (ko) 2017-06-28 2025-10-28 리제너론 파아마슈티컬스, 인크. 항-인간 유두종 바이러스 (hpv) 항원-결합 단백질 및 그의 사용 방법
KR20200104284A (ko) 2017-10-03 2020-09-03 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
AU2019247200A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
CN112585277A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 表达重组受体的t细胞、相关多核苷酸和方法

Also Published As

Publication number Publication date
KR102764123B1 (ko) 2025-02-05
CO2020013499A2 (es) 2021-01-18
JP7410868B2 (ja) 2024-01-10
BR112020019313A2 (pt) 2021-01-05
CN112566698A (zh) 2021-03-26
WO2019195486A1 (en) 2019-10-10
US11471489B2 (en) 2022-10-18
TWI840351B (zh) 2024-05-01
RU2020135968A (ru) 2022-05-06
MA52193A (fr) 2021-02-17
IL277703A (en) 2020-11-30
JP2021520198A (ja) 2021-08-19
TW202005658A (zh) 2020-02-01
MX2020010460A (es) 2021-01-29
SG11202009284TA (en) 2020-10-29
KR20210019993A (ko) 2021-02-23
EP3773908A1 (en) 2021-02-17
CL2020002545A1 (es) 2021-01-29
US20230256018A1 (en) 2023-08-17
CA3095027A1 (en) 2019-10-10
AU2019249209A1 (en) 2020-10-15
US20190321401A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
PE20201345A1 (es) Receptores de celulas t, y celulas disenadas que expresan los mismos
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
AR127117A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
AR121380A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
MX2021015933A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de prostata y otros tipos de cancer.
MX2021013147A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres.
MX2017017145A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres.
PE20230768A1 (es) Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de pulmon, incluido el cancer de pulmon amicrocitico y otros tipos de cancer
MX2020010035A (es) Receptores de celulas t anti-papilomavirus 16 e7 humano.
MX2019006724A (es) Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
MX2018002480A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
EA201792484A1 (ru) Новые клеточные эпитопы и комбинации клеточных эпитопов для применения в иммунотерапии миеломы и других видов рака
MX2018011225A (es) Celulas t transfectadas y receptores de celulas t de utilidad en inmunoterapias contra el cancer.
AR112604A1 (es) Receptores de células t, e inmunoterapia usando los mismos
MX2021013003A (es) Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra cancer esofagico y otros canceres.
MX2018007842A (es) Nueva generacion de tcr especificos de antigeno.
CR20220115A (es) PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Div. 2017-522)
MX2022001319A (es) Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer.
UY37630A (es) Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer
MX2019012226A (es) Peptidos y combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cancer.
AR119644A1 (es) Receptores de celulas t, y celulas diseñadas que expresan los mismos
CY1124826T1 (el) Υποδοχεις τ-κυτταρων και ανοσοθεραπεια με τη χρηση των ιδιων
AR121812A2 (es) Péptido, vector de expresión, célula huésped, linfocito t activado, anticuerpo, receptor de células t, composición farmacéutica, kit y métodos relacionados
AR105252A1 (es) Péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres